Abstract
Objectives To estimate time trends in cigarette consumption among smokers in England between 2008 and 2023, and explore differences by key potential moderators.
Methods We used data from 57,778 adult cigarette smokers participating in a nationally-representative monthly cross-sectional survey between January-2008 and September-2023. We estimated monthly time trends in mean daily consumption of (i) any, (ii) manufactured, and (iii) hand-rolled cigarettes among all smokers and by main type of cigarettes smoked, smoking frequency, age, gender, occupational social grade, region, nicotine replacement therapy use, and vaping status.
Results Overall cigarette consumption fell from 13.6 [95%CI=13.3-13.9] to 10.6 [10.5-10.8] per day between January-2008 and October-2019 (a 22% decrease), then remained stable up to September-2023. Over this period, the proportion mainly/exclusively smoking hand-rolled cigarettes increased (from 30.6% [29.1-32.1%] in 2008 to 52.1% [49.7-54.5%] in 2023). As a result, manufactured cigarette consumption fell by 47%, from 9.5 [9.2-9.8] per day in January-2008 to 5.0 [4.7-5.3] in September-2023, while hand-rolled cigarette consumption increased by 35%, from 4.2 [3.9-4.4] to 5.6 [5.3-5.9]. The decline in overall cigarette consumption was observed across all subgroups, but was greater among non-daily smokers, younger smokers, and those who vaped.
Conclusions Over the last 15 years, the average number of cigarettes consumed each day by smokers in England has fallen by almost a quarter, but has plateaued since October-2019. There has been a sharp decline in the number of manufactured cigarettes consumed and an increase in the number of hand-rolled cigarettes consumed, as smokers have increasingly shifted towards using hand-rolled tobacco.
Competing Interest Statement
Jamie Brown has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. Lion Shahab has received honoraria for talks, an unrestricted research grant and travel expenses to attend meetings and workshops from Pfizer, and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Clinical Protocols
Funding Statement
Cancer Research UK (PRCRPG-Nov21\100002) funded the Smoking Toolkit Study data collection and the salaries of Sarah Jackson and Harry Tattan-Birch. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the STS was granted originally by the UCL Ethics Committee (ID 0498/001). The data are not collected by UCL and are anonymized when received by UCL.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
